Opendata, web and dolomites

EPIPHARM SIGNED

Development of a ncRNA DNA Methylation Kit for Treatment Guidance in Cancer of Unknown Primary

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EPIPHARM project word cloud

Explore the words cloud of the EPIPHARM project. It provides you a very rough idea of what is the project "EPIPHARM" about.

empiric    tool    personalized    outcome    prognoses    comprise    pharmacological    ncrna    validation    profile    heterogeneous    erc    mentioned    showed    human    patients    50    usually    company    health    immunohistochemistry    epinorc    drug    treatments    sensitivity    first    therapy    variety    taxane    poc    recommended    diagnoses    epipharm    benefit    micrornas    undergoing    despite    primary    rnas    lincrnas    idea    group    chemotherapy    ucrs    regimens    ncrnas    licensed    tools    cancers    image    dismal    pattern    coding    grant    allowed    world    introduction    rna    anonymous    epigenetic    tumor    successful    presentation    approximately    demonstrating    modest    extremely    cpg    snornas    pirnas    cancer    epigenotyping    final    fingerprint    proof    guide    platinum    clinical    regarding    loci    interesting    plan    six    assay       diagnosis    disease    commercially    innovative    methylation    pharmacogenetics    poor    feasibility    providers    reported    cup    cups    dna    technologies    months    origin    throughput    epicup    disruption    treatment    unknown    metastatic    site    gemcitabine    death    optimize    epigenetics   

Project "EPIPHARM" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE 

Organization address
address: AVENIDA GRAN VIA HOSPITALET 199-203
city: L'HOSPITALET DE LLOBREGAT
postcode: 8908
website: www.idibell.cat

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 149˙345 €
 EC max contribution 149˙345 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2018-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE ES (L'HOSPITALET DE LLOBREGAT) coordinator 119˙345.00
2    XENOPAT SL ES (HOSPITALET DE LLOBREGAT) participant 30˙000.00

Map

 Project objective

The innovative idea behind the EPIPHARM (EPIgenetics of PHARMacogenetics) project is to develop a package demonstrating the feasibility of a high-throughput tool for epigenotyping Cancer of Unknown Primary (CUP) to identify a drug sensitivity fingerprint based in the DNA methylation profile of non-coding RNA (ncRNA) loci. CUPs are a heterogeneous group of cancers defined by the presence of metastatic disease with no identified primary tumor at presentation. The CUP outcome is extremely poor with an expected death within the first six months of the diagnosis. CUP has been reported to comprise approximately 5% of all cancer cases in the world. Despite the introduction of new image technologies and immunohistochemistry methods, more than 50% of CUPs remain anonymous regarding their primary tumor site of origin and, as mentioned, their prognoses are dismal. For most patients with CUP, recommended treatments involves just empiric chemotherapy, usually with a taxane/platinum or gemcitabine/platinum regimens that achieve the described modest clinical benefit. Thus, it is necessary to have better tools to guide the pharmacological treatment of CUP cases. As part of the ERC Advanced Grant “Epigenetic Disruption on Non-Coding RNAs in Human Cancer” (EPINORC) we identified CpG methylation changes in a wide variety of ncRNAs (microRNAs, lincRNAs, T-UCRs, snoRNAs, piRNAs...) that showed a tumor-type specific pattern that has allowed the successful development of the EPICUP assay for the diagnoses of CUPs that it has been licensed and it is undergoing final clinical validation. In the current EPIPHARM Proof of Concept (PoC) proposal, we plan to optimize a ncRNA DNA methylation assay that includes a user-friendly and cost effective approach to improve the therapy of CUP cases by providing a more personalized drug treatment to an extent that will make it interesting commercially for the health providers and their associated company partners.

 Publications

year authors and title journal last update
List of publications.
2018 Michäel Duruisseaux, Anna Martínez-Cardús, Maria E Calleja-Cervantes, Sebastian Moran, Manuel Castro de Moura, Veronica Davalos, David Piñeyro, Montse Sanchez-Cespedes, Nicolas Girard, Marie Brevet, Etienne Giroux-Leprieur, Coraline Dumenil, Monica Pradotto, Paolo Bironzo, Enrica Capelletto, Silvia Novello, Alexis Cortot, Marie-Christine Copin, Niki Karachaliou, Maria Gonzalez-Cao, Sergio Peralta, Luis M Montuenga, Ignacio Gil-Bazo, Iosune Baraibar, Maria D Lozano, Mar Varela, Jose C Ruffinelli, Ramon Palmero, Ernest Nadal, Teresa Moran, Lidia Perez, Immaculada Ramos, Qingyang Xiao, Agustin F Fernandez, Mario F Fraga, Marta Gut, Ivo Gut, Cristina Teixidó, Noelia Vilariño, Aleix Prat, Noemi Reguart, Amparo Benito, Pilar Garrido, Isabel Barragan, Jean-François Emile, Rafael Rosell, Elisabeth Brambilla, Manel Esteller
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
published pages: 771-781, ISSN: 2213-2600, DOI: 10.1016/S2213-2600(18)30284-4
The Lancet Respiratory Medicine 6/10 2019-04-03
2017 Sebastián Moran, Anna Martinez-Cardús, Stergios Boussios, Manel Esteller
Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary
published pages: 682-694, ISSN: 1759-4774, DOI: 10.1038/nrclinonc.2017.97
Nature Reviews Clinical Oncology 14/11 2019-04-03
2018 Humberto J. Ferreira, Veronica Davalos, Manuel Castro de Moura, Marta Soler, Montserrat Perez-Salvia, Alberto Bueno-Costa, Fernando Setien, Sebastian Moran, Alberto Villanueva, Manel Esteller
Circular RNA CpG island hypermethylation-associated silencing in human cancer
published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.25673
Oncotarget 9/49 2019-04-03

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIPHARM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPIPHARM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

E-DIRECT (2020)

Evolution of Direct Reciprocity in Complex Environments

Read More  

HYDROGEN (2019)

HighlY performing proton exchange membrane water electrolysers with reinforceD membRanes fOr efficient hydrogen GENeration

Read More  

REPLAY_DMN (2019)

A theory of global memory systems

Read More